Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lemonade Inc (LMND) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Lemonade IncTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Lemonade Inc vs Neurocrine Biosciences Inc — how do they compare? Lemonade Inc trades at $51.3 (market cap $4.09B), while Neurocrine Biosciences Inc trades at $156.76 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 4× Lemonade Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals.

LMNDNBIX
Market Cap
$4.09B$16.46B
Sector
FinancialsHealth
52-Week High
$96.57$185.50
52-Week Low
$47.38$123.10
Enterprise Value
$3.95B$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lemonade Inc

Lemonade (LMND) trades at $51.21, down 2.79% in the past 24 hours, with a bearish technical signal indicated by moving averages and ADX. The company reported Q2 2026 earnings that beat expectations, with revenue growth of 79% year-over-year, but remains unprofitable with a net income margin of -14.19%. Recent news highlights a CFO transition and expansion into new states, while the stock faces volatility amid mixed analyst sentiment.

The outlook for LMND hinges on achieving profitability, guided for Q4 2026, but high valuation (P/S of 4.1) and persistent losses pose risks. Opportunities include AI-driven growth and market expansion, yet investors face execution risks and competitive pressures in the insurance sector.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Lemonade Inc

Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.

Read more on LMND

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX